

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6224416

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	JOHNSON & JOHNSON (CHINA) INVESTMENT LTD.	06/27/2017
RECEIVING PARTY DATA		
Name:	JANSSEN PHARMACEUTICA NV	
Street Address:	TURNHOUTSEWEG 30	
City:	BEERSE	
State/Country:	BELGIUM	
Postal Code:	B-2340	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16623011
CORRESPONDENCE DATA		
Fax Number:	(215)568-3439	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	assignments@woodcock.com	
Correspondent Name:	BAKER & HOSTETLER LLP	
Address Line 1:	2929 ARCH STREET, CIRA CENTRE	
Address Line 2:	12TH FLOOR	
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19104	
ATTORNEY DOCKET NUMBER:	103693.002168	
NAME OF SUBMITTER:	VALERIE CHICCHI	
SIGNATURE:	/Valerie Chicchi/	
DATE SIGNED:	07/29/2020	
Total Attachments: 2		
source=GENERAL_ASSIGNMENT_J_JCHINA_TO_JANSSEN#page1.tif		
source=GENERAL_ASSIGNMENT_J_JCHINA_TO_JANSSEN#page2.tif		

General Assignment

WHEREAS, Johnson & Johnson (China) Investment Ltd., having its place of business at 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai, China (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"New Quinolone compounds"

for which on the 27th day of June 2017, International Patent Application no. PCT/CN2017/090267 was filed at the Chinese Patent Office.

WHEREAS, Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, except for the Seychelles, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 27th day of June 2017.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Johnson & Johnson (China) Investment Ltd.

For Janssen Pharmaceutica NV



, Authorized Signatory

Frank Daelemans, Authorized Signatory

General Assignment

WHEREAS, Johnson & Johnson (China) Investment Ltd., having its place of business at 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai, China (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"NEW QUINOLINONE COMPOUNDS"

for which on the 27th day of June 2017, International Patent Application no. PCT/CN2017/090267 was filed at the Chinese Patent Office.

WHEREAS, **Janssen Pharmaceutica NV**, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,


NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns for the Seychelles, to said Assignee co-applicant rights, including the right to claim priority, in and to all said inventions disclosed in said application and in and to said application, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns.

The Assignor agrees that this general assignment is effective from the 27th day of June 2017.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Johnson & Johnson (China) Investment Ltd.

For Janssen Pharmaceutica NV



Lisbeth Vervant, Authorized Signatory